Tyra Biosciences Inc
TYRAHealthcare|Biotechnology|USA
$32.75
-0.26 (-0.79%)
Tangible Book
$6.52
Earnings Power
$6.02
Financials
Financial Snapshot
Market Cap
$1.95B
Enterprise Value
$377.8M
Revenue (TTM)
$0.00
Net Income (TTM)
$-131.1M
Cash & Equivalents
—
Net Cash/Share
$6.04
Free Cash Flow (TTM)
$-102.5M
Operating CF (TTM)
$-102.3M
Debt/Equity
0.02
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$25.6M
Monthly Burn
$8.5M
Est. Runway
—
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $108.0K | $15.2M | $302.2M | $251.2M | $203.5M | $341.4M | $256.0M | $383.5M | |
| Operating Cash Flow | $-2.6M | $-7.8M | $-23.7M | $-50.3M | $-50.1M | $-69.8M | $-95.1M | $-102.3M | |
| Free Cash Flow | $-2.6M | $-8.1M | $-24.4M | $-50.8M | $-50.9M | $-70.4M | $-95.3M | $-102.5M | |
| Capital Expenditure | $-20.0K | $-312.0K | $-661.0K | $-559.0K | $-770.0K | $-664.0K | $-141.0K | $-215.0K | |
| Financing Cash Flow | $157.0K | $23.4M | $311.3M | $632.0K | $1.5M | $202.1M | $8.1M | $166.3M |
R&D Spending
R&D (TTM)
$111.4M
R&D Intensity
—
R&D Growth YoY
+8.3%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.8M | $7.2M | $20.6M | $43.0M | $62.5M | $80.1M | $102.9M | $111.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | |
| SG&A | $1.3M | $2.1M | $5.7M | $15.9M | $17.4M | $24.1M | $29.8M | $31.5M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $1.8M | $7.2M | $20.6M | $43.0M | $62.5M | $80.1M | $102.9M | $111.4M | |
| SG&A | $1.3M | $2.1M | $5.7M | $15.9M | $17.4M | $24.1M | $29.8M | $31.5M | |
| Operating Income | $-3.1M | $-9.3M | $-26.3M | $-58.9M | $-79.9M | $-104.2M | $-132.8M | $-142.9M | |
| Interest Expense | $-1.0K | $-1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-4.1M | $-9.3M | $-26.3M | $-55.3M | $-69.1M | $-86.5M | $-119.9M | $-131.1M | |
| Net Income | $-4.1M | $-9.3M | $-26.3M | $-55.3M | $-69.1M | $-86.5M | $-119.9M | $-131.1M | |
| EPS (Diluted) | -0.40 | -0.41 | -1.91 | -1.32 | -1.62 | -1.51 | -2.01 | -2.18 | |
| EBITDA | $-4.1M | $-9.3M | $-26.1M | $-58.6M | $-79.6M | $-103.7M | $-132.2M | $-142.4M | |
| Shares Out. (M) | 10.19 | 22.48 | 13.78 | 41.88 | 42.70 | 57.22 | 59.60 | 61.75 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $108.0K | $15.2M | $302.2M | $251.2M | $58.0M | $92.0M | $77.4M | $85.0M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $145.5M | $249.5M | $178.6M | $298.5M | |
| Total Current Assets | $127.0K | $15.3M | $304.1M | $257.3M | $211.7M | $347.5M | $265.4M | $394.6M | |
| Total Assets | $528.0K | $16.0M | $306.7M | $266.2M | $225.9M | $363.6M | $282.6M | $412.0M | |
| Total Current Liabilities | $5.2M | $1.9M | $3.6M | $5.7M | $15.3M | $14.6M | $18.1M | $19.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $5.3M | $29.6M | $5.0M | $8.4M | $21.6M | $20.4M | $23.4M | $24.5M | |
| Stockholders' Equity | $-4.7M | $-13.6M | $301.7M | $257.8M | $204.3M | $343.2M | $259.2M | $387.6M | |
| Retained Earnings | $-4.7M | $-14.1M | $-40.4M | $-95.7M | $-164.8M | $-251.3M | $-371.3M | $-410.6M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-2.6M | $-7.8M | $-23.7M | $-50.3M | $-50.1M | $-69.8M | $-95.1M | $-102.3M | |
| Capital Expenditure | $-20.0K | $-312.0K | $-661.0K | $-559.0K | $-770.0K | $-664.0K | $-141.0K | $-215.0K | |
| Free Cash Flow | $-2.6M | $-8.1M | $-24.4M | $-50.8M | $-50.9M | $-70.4M | $-95.3M | $-102.5M | |
| Investing Cash Flow | $-20.0K | $-312.0K | $-645.0K | $-559.0K | $-144.6M | $-98.4M | $72.5M | $-79.8M | |
| Financing Cash Flow | $157.0K | $23.4M | $311.3M | $632.0K | $1.5M | $202.1M | $8.1M | $166.3M | |
| Issuance of Stock | $0.00 | $0.00 | $181.2M | $0.00 | $0.00 | $200.0M | $0.00 | $147.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-420.0K | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $-8.0K | $-17.0K | $-9.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $439.0K | $2.9M | $10.6M | $13.5M | $22.8M | $28.0M | $29.4M | |
| Net Change in Cash | $-2.5M | $15.4M | $287.0M | $-50.2M | $-193.2M | $34.0M | $-14.6M | $-15.8M |
Dilution Tracker
Shares outstanding grew 348.1% over 5 years — significant dilution
Shares Outstanding
62M
5-Year Share Growth
+348.1%
Stock Issuance (TTM)
$147.9M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 10.19 | 22.48 | 13.78 | 41.88 | 42.70 | 57.22 | 59.60 | 61.75 | |
| YoY Change % | — | 120.7% | -38.7% | 203.9% | 2.0% | 34.0% | 4.2% | 3.6% | |
| Stock Issuance | $0.00 | $0.00 | $181.2M | $0.00 | $0.00 | $200.0M | $0.00 | $147.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-420.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $439.0K | $2.9M | $10.6M | $13.5M | $22.8M | $28.0M | $29.4M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | -18.3% | -19.8% | -29.9% | -31.6% | -39.8% | -42.2% | |
| ROA % | -769.9% | -112.9% | -16.3% | -19.3% | -28.1% | -29.3% | -37.1% | -39.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B5.03
Historical— / — / 5.03
Industry Med.2.93
EV/EBITDA-11.03
Historical-11.03 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$6.52
Net Current Assets
$6.220
Net-Net Working Capital
$6.04
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 1.93 | 1.25 | 2.92 | 2.06 | 5.45 | 5.03 | |
| EV/EBITDA | 0.00 | 0.00 | -10.79 | -1.25 | -5.01 | -3.57 | -8.79 | -11.03 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
1
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $8.30M |
| Net Income | $-164.45M | $-191.11M | $-210.05M |
| EPS | -2.59 | -2.84 | -3.02 |
| Book Value per Share | 2.23 | 2.89 | 0.00 |
| Operating Cash Flow per Share | -2.19 | -2.24 | 0.00 |
| Operating CF | $-135.22M | $-138.31M | $0.00M |